Menu
Washingtoner
  • Home
  • Health
  • Technology
  • Artificial Intelligence
  • Real Estate
  • Non-profit
  • Financial
  • Business
  • Concealed Carry
Washingtoner

Myosana Therapeutics Raises $5 Million in Seed Funding
Washingtoner/10205303

Trending...
  • King Larry Steps Into His Moment With Music, Major Performances and a Story Built on Persistence
  • South Tacoma Glass Recycling Drop-Off Location Closing
  • Tacoma: Hylebos Bridge to Close September 8 – 10 for Routine Structural Inspection
SEATTLE--(BUSINESS WIRE)--Myosana Therapeutics, Inc., pioneer of a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases, today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D. The capital will go toward developing Myosana's platform with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.

"Built on decades of expertise in neuromuscular diseases, Myosana's muscle-specific non-viral gene therapy platform is poised to change the way patients are treated for neuromuscular and cardiac diseases," said Ballantyne, Cofounder and former longtime CSO of Biologics CDMO-Aldevron, and a Founder of therapeutic delivery system developer Agathos. "Myosana's progress building on the platform's promising in vivo data is an essential next step. I'm excited to partner with the company as it pushes ahead toward a therapy that will reach patients and improve their lives."

New investments from the Muscular Dystrophy Association and Parent Project Muscular Dystrophy (PPMD) rounded out the seed round, building on capital from original Myosana investor CureDuchenne Ventures and early investor PPMD a year later.

More on Washingtoner
  • PeopleNTech LLC to Participate in CWS Summit North America 2026
  • Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
  • STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
  • Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
  • Tidy-Up Tacoma Teams Up with Community Partners for Citywide Cleanup Event September 19

Completion of this major funding round comes just as Myosana has appointed its new CEO, Dr. Matthew Lumley. A board member since 2021, Lumley is a physician scientist who has spent nearly two decades in academic medicine and drug development, cultivating expertise in translational medicine and early clinical development in complex pediatric diseases. Lumley is also the father of a son with Duchenne muscular dystrophy. In his role on Myosana's Board of Directors, Lumley has been intimately involved in raising seed funding and advancing the platform.

"Dr. Ballantyne's expertise in the nucleic acid production and delivery spaces builds credibility in our approach. His investment, alongside our nonprofit partners, will go directly to platform optimization and the identification of a development candidate for Duchenne muscular dystrophy in the next 18-24 months," said Lumley. "As proof of principle for the platform, success in treating Duchenne would open up opportunities for Myosana to target a large range of neuromuscular and cardiac diseases."

Alongside his role as CEO of Myosana, Lumley is a Venture Partner at Medicxi, a life sciences-focused venture capital firm where he is involved in the formation and financing of biotechnology companies across the full drug development continuum. His recent roles include Senior Director of Rare Disease Clinical Development at Moderna and Medical Director of Rare Diseases at Pfizer.

About Myosana Therapeutics

Myosana Therapeutics, Inc., has pioneered a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases. Based on this platform, the company is developing new gene therapies that will potentially transform progressive neuromuscular and cardiac diseases, increasing longevity and improving quality of life. Myosana's first clinical candidate from the platform will be delivery of full-length dystrophin as a therapy for Duchenne muscular dystrophy.

More on Washingtoner
  • Lynnwood Heating LLC Helps Homeowners Take Advantage of 2026 Heat Pump Installation Rebates
  • Tacoma: Applicants Sought for the Board of Ethics
  • Tacoma: Applicants Sought for the Landmarks Preservation Commission
  • Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
  • Mandeville Pests May Pose Serious Health Risks for Your Family

Myosana's esteemed leadership team includes cofounders Stan Froehner, Ph.D., and Nick Whitehead, Ph.D., both internationally known experts in neuromuscular disease from the University of Washington, whose decades-long careers are marked by significant milestones. Dr. Froehner discovered the syntrophin proteins in muscle's dystrophin complex and developed several pre-clinical treatments for muscular dystrophy. Dr. Whitehead has uncovered mechanisms of muscle weakness in Duchenne muscular dystrophy and developed Myosana's innovative non-viral platform. The platform overcomes the significant limitations of viral vector-delivered gene therapy for muscle disease by providing targeted muscle delivery, large gene capacity, repeat dosing, and immune neutrality.

To learn more and follow Myosana's progress toward its first clinical development candidate, visit us at www.myosanatherapeutics.com.

Contacts

Kara Stephens-Weaver
407-765-1185
kara.stephens-weaver@precisionvh.com
Show All News | Disclaimer | Report Violation

1 Comment
1000 characters max.

  • unity asset store.:
    Build real-time 3D projects for various industries across games, animation, automotive, architecture, and more with Unity Asset Store. Start creating with Unity today!
Latest on Washingtoner
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!
  • Dividend Stacker Launches Free Calendar and Alerts for High-Yield ETF Payouts
  • Announcing the NCIHC 2026 Language Access Champion Awardees
  • Paul Ohana - From Beverly Hills Salon Chair To Beauty Founder Celebrity Hair Expert
  • Best Band You Never Heard Of Breaks Up
  • ChargeOn Announces Conversational Payment Management Solution
  • South Tacoma Glass Recycling Drop-Off Location Closing
  • King Larry Steps Into His Moment With Music, Major Performances and a Story Built on Persistence
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center
  • Labor Day Observed by City of Tacoma on September 7
  • Tacoma: Hylebos Bridge to Close September 8 – 10 for Routine Structural Inspection
  • Redefining Proactive Care: The Rise of the Hybrid Concierge Medical Model
  • As Canada and America Turn on Each Other, These Two Authors Stay On Speaking Terms
  • Baba Farid LLC Introduces SpaceGen AI and Mingora AI OS
  • GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration
  • Brévant Guide Launches New National Restaurant Guide Across Canada
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not
  • Marti Reeder Ranked Among Washington State's Top Real Estate Brokers by RealTrends Verified
  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing
  • VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: SPD Arrest Level III Registered Sex Offender for Failure to Register - 552
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support - 218
  • On the Boards: Proform Builds Announce New Construction in Alki, Seattle - 152
  • Diginyze eCommerce ERP Module Creates Single Source of Truth for Enterprise Operations - 145
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism - 132
  • Continuous You Foundation Opens Applications For A 100-year Artist Grant - 123
  • Tacoma: Applications Now Being Accepted for a Position on the Planning Commission - 114
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 113
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs - 112
  • Tacoma: Hylebos Bridge Closed Today for Maintenance Work

Similar on Washingtoner

  • Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
  • STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
  • Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
  • Mandeville Pests May Pose Serious Health Risks for Your Family
  • ChargeOn Announces Conversational Payment Management Solution
  • VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8
  • Volant Announces Major Partnership with the STEM Racing Canada Program to CHAMPION YOUTH ENGINEERING
  • 54 Million Contract. New Chapter as AI Cybersecurity Platform Expands, Margins Surge & Management Signals Confidence. Cycurion, Inc: (NAS DAQ: CYCU)
  • Work 365 Deepens TD SYNNEX Integration with Automated Azure Billing
  • RAS AP Consulting Signals Growth of Managed AP Governance With Digital Expansion, Pipeline Activation, and Trademark Filing Ahead of Esker All Access
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute